Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Hepatitis C virus (HCV) prevalence among transgender and gender-diverse individuals ranges from 1.8% to 15.7% versus 1% in the general population. Previous HCV studies inclusive of transgender and gender-diverse individuals primarily rely on convenience-based sampling methods or are geographically restricted. The purpose of this study is to compare the prevalence of HCV diagnoses, testing, and care engagement between transgender and gender-diverse and cisgender individuals.
Methods: Using Optum's de-identified Clinformatics® Data Mart Database, in 2022, the unadjusted prevalence of HCV testing among all adults and people who inject drugs from January 2001 to December 2019 was measured. Multivariable logistic regression was used to compare the adjusted odds of HCV diagnoses and care engagement by gender subgroup.
Results: The overall unadjusted frequency of HCV diagnoses among transgender and gender-diverse individuals was approximately 3 times that of cisgender individuals (1.06% vs 0.38%, p<0.001), including among people who inject drugs (6.36% vs 2.36%, p=0.007). Compared with cisgender women, transfeminine/nonbinary individuals had over 5 times the adjusted odds of a HCV diagnosis and approximately 3.5 times the odds of being tested for HCV. In addition, compared with cisgender women, transfeminine/nonbinary individuals had significantly increased odds of having a HCV‒related procedure (e.g., abdominal ultrasounds, liver biopsies, Fibroscans). Cisgender men had significantly increased odds of receiving HCV medication compared with cisgender women.
Conclusions: Although testing was higher among transgender and gender-diverse individuals, the higher overall frequency of HCV diagnoses among transgender and gender-diverse than among cisgender individuals signals persistent health disparities. Interventions are warranted to prevent HCV and increase ongoing testing and treatment uptake among transgender and gender-diverse populations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121731 | PMC |
| http://dx.doi.org/10.1016/j.amepre.2023.01.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Burden of Cancer and Precancerous Conditions Among Transgender Individuals in a Large Health Care Network: Retrospective Cohort Study.
JMIR Cancer
September 2025
Department of Health Outcomes and Biomedical Informatics, University of Florida, 1889 Museum Road, Suite 7000, Gainesville, FL, 32611, United States, 1 352 294-5969.
Background: Disparities in cancer burden between transgender and cisgender individuals remain an underexplored area of research.
Objective: This study aimed to examine the cumulative incidence and associated risk factors for cancer and precancerous conditions among transgender individuals compared with matched cisgender individuals.
Methods: We conducted a retrospective cohort study using patient-level electronic health record (EHR) data from the University of Florida Health Integrated Data Repository between 2012 and 2023.
Digital Hostility Toward LGBTQIA+ Research Recruitment on Social Media Using Topic Modeling and Sentiment Analysis of Facebook Comments: Quantitative Content Analysis Study.
J Med Internet Res
September 2025
Department of Psychological and Brain Sciences, Boston University, Boston, United States.
Background: Lesbian, gay, bisexual, transgender, queer/questioning, intersex, asexual (LGBTQIA+) researchers and participants frequently encounter hostility in virtual environments, particularly on social media platforms where public commentary on research advertisements can foster stigmatization. Despite a growing body of work on researcher virtual hostility, little empirical research has examined the actual content and emotional tone of public responses to LGBTQIA+-focused research recruitment.
Objective: This study aimed to analyze the thematic patterns and sentiment of social media comments directed at LGBTQIA+ research recruitment advertisements, in order to better understand how virtual stigma is communicated and how it may impact both researchers and potential participants.
Gender Identity and Gender-Related Medical Outcomes of Autistic Young Adults Who Experienced Transgender Identity as Adolescents.
Transgend Health
September 2025
Center for Neuroscience, Children's National Hospital, Washington, District of Columbia, USA.
Purpose: We examined gender identity and gender-affirming care outcomes of autistic transgender adolescents followed into young adulthood, as well as relationships between gender-related medical care receipt and mental health across time.
Methods: This longitudinal two-timepoint study was conducted between 2018 and 2024, with 4 years between timepoints. Twenty-seven autistic transgender youth participated, with one lost to follow-up.
Covariate adjustment in LGBTQ+ health disparities research: aligning methods with assumptions.
Am J Epidemiol
September 2025
Department of Epidemiology, Harvard T.H. Chan School of Public Health.
In 2016, the NIH designated LGBTQ+ individuals (ie, lesbian, gay, bisexual, transgender, queer, and all sexual and gender minorities) as a health disparities population. The growing interest in studying the health of LGBTQ+ populations merits revisiting the methodological approaches researchers employ. We elucidate how researchers can identify appropriate adjustment sets for causal questions using directed acyclic graphs (DAGs).
View Article and Find Full Text PDFNon-Sedated Intrauterine Device Experiences Among Transgender and Cisgender Adolescents and Young Adults in the Outpatient Setting.
J Pediatr Adolesc Gynecol
September 2025
Division of Adolescent Medicine, Seattle Children's Hospital, Seattle, WA, USA.
Study Objectives: This study compares the demographic characteristics and experiences of three different groups of adolescent and young adults (AYAs) seeking non-sedated intrauterine device (IUD) insertion in the outpatient setting: (1) cisgender individuals, (2) transgender and gender diverse (TGD) individuals receiving gender-affirming testosterone therapy, and (3) TGD individuals not receiving gender-affirming testosterone therapy.
Methods: This retrospective cohort study included AYAs age 13 to 21 years seeking IUD insertion. Data were obtained from the electronic health record via a pre-existing, multi-institutional shared quality improvement (QI) collaborative.